U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06879379) titled 'KPD Consolidation After ASCT in NDMM Patients' on March 11.
Brief Summary: This study aims to evaluate the efficacy and safety of post-transplant consolidation therapy with the KPD regimen (carfilzomib, pomalidomide, and dexamethasone) versus no consolidation, followed by maintenance therapy, in patients with transplant-eligible newly diagnosed multiple myeloma (TE-NDMM). The primary goal is to compare minimal residual disease (MRD) negativity rates and overall treatment outcomes between the two groups.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma, Newly Diagnosed
Intervention:
DRUG: KP...